Chinese gene-editing therapeutics company developing potentially curative medicines for genetic and complex diseases
Chinese gene-editing therapeutics company developing potentially curative medicines for genetic and complex diseases. Its pipeline includes therapies for beta- and alpha-thalassemia and Usher syndrome, with research extending to cardiovascular, metabolic, infectious, and autoimmune diseases. Platforms combine genomics and AI for target discovery, CRISPR/Cas and base editing, and ex vivo cell engineering or in vivo delivery using LNPs or AAV.